XML 70 R60.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

SUBSEQUENT EVENTS (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | ---
Apr. 01, 2024 | Mar. 08, 2024 | May 13, 2024 | Jun. 30, 2024 | Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023
Subsequent Event [Line Items] |  |  |  |  |  |  |  |
Loss from change in fair value of derivative liabilities |  |  |  |  | $ (1,959,000) | $ (14,000) | $ (1,991,000) | $ (40,000)
Warrant derivative liability |  |  |  |  | 7,647,000 |  | 7,647,000 |
Securities exchange agreement |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |
Outstanding shares percentage |  | 7.00% |  |  |  |  |  |
Securities exchange agreement | Exchange Pre-Funded Warrants |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |
Warrants exercisable, ownership blocker percentage |  | 9.99% |  |  |  |  |  |
Outstanding shares percentage |  | 7.00% |  |  |  |  |  |
Change in fair value of derivative liability |  |  |  |  | 1,950,000 |  | 1,950,000 |
Warrant derivative liability |  | $ 5,700,000 |  |  | $ 7,600,000 |  | 7,600,000 |
Scenario, Upon First Dosing Of The First Patient | XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |
Milestone closing payment |  |  |  |  |  |  | $ 5,000,000.0 |
Maximum | Securities exchange agreement | Exchange Pre-Funded Warrants |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |
Warrants exercisable, ownership blocker percentage |  | 19.99% |  |  |  |  |  |
Subsequent Event | Securities exchange agreement | Exchange Pre-Funded Warrants |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |
Change in fair value of derivative liability |  |  | $ 900,000 |  |  |  |  |
Loss from change in fair value of derivative liabilities |  |  |  | $ (900,000) |  |  |  |
Warrant derivative liability |  |  | $ 8,600,000 |  |  |  |  |
Subsequent Event | Scenario, Upon First Dosing Of The First Patient | XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |
Milestone closing payment | $ 5,000,000.0 |  |  |  |  |  |  |

X
- Definition The amount of change in fair value of warrant derivative liability. + References No definition available. + Details
Name: | rzlt_ChangeInFairValueOfWarrantDerivativeLiability
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of milestone payment made during the period. + References No definition available. + Details
Name: | rzlt_MilestoneClosingPayment
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of stock acquired to the total of outstanding shares. + References No definition available. + Details
Name: | rzlt_PercentageOfTreasuryStockAcquiredOfSharesOutstanding
Namespace Prefix: | rzlt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value as of the balance sheet date of the warrants derivative classified as a liability. + References No definition available. + Details
Name: | rzlt_WarrantDerivativeLiabilityNonCurrent
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants. + References No definition available. + Details
Name: | rzlt_WarrantsExercisableOwnershipBlockerPercentage
Namespace Prefix: | rzlt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A + Details
Name: | us-gaap_GainLossOnDerivativeInstrumentsNetPretax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | rzlt_AgreementAxis=rzlt_SecuritiesExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=rzlt_ScenarioUponFirstDosingOfFirstPatientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz358Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |